|
2025
|
G/S
|
Pharmaceutical preparations and substances for the treatment of cardiovascular, renal, hepatologi... |
|
|
G/S
|
Pharmaceutical preparations and substances. |
|
|
G/S
|
Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for the treatment of... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of diseases and disorders of the ren... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of diseases and disorders of the cardiovascular, re... |
|
|
G/S
|
Pharmaceutical preparations and substances. |
|
|
G/S
|
Pharmaceutical preparations and substances for use in oncology. |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cardiovascular, metabolic, and renal diseases an... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment
of respiratory diseases and disorders. |
|
|
Invention
|
Polq inhibitors.
The specification generally relates to compounds of Formula (I):
The specific... |
|
|
Invention
|
Stable, aqueous formulations of antibodies that bind il5 receptor.
The present invention relates... |
|
|
Invention
|
2,6,9-trisubstituted purines.
Compounds having the structure of Formula (I):
Compounds having ... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of cardiovascular, metabolic, and re... |
|
|
G/S
|
Pharmaceutical preparations and substances |
|
2024
|
Invention
|
Death receptor 5 (dr5)-armored car-t therapeutic. This disclosure relates to compositions and met... |
|
|
Invention
|
Combination of zibotentan and dapagliflozin for the treatment of microvascular angina. Methods fo... |
|
|
Invention
|
Irak4 protacs.
This specification relates to compounds according to Formula (I), which are PROTA... |
|
|
Invention
|
Irak4 protacs. This specification relates to compounds according to Formula (I), which are PROTAC... |
|
|
Invention
|
Methods of treating chronic kidney disease with dapagliflozin.
The present disclosure is directe... |
|
|
Invention
|
Pharmaceutical compositions comprising (2s)-n-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-... |
|
|
Invention
|
Er degraders and uses thereof.
This specification relates to compounds according to Formula (I),... |
|
|
Invention
|
Er degraders and uses thereof. This specification relates to compounds according to Formula (I), ... |
|
|
Invention
|
Heteroaromatic 17beta hydroxy steroid dehydrogenase 13 inhibitors. The specification relates to c... |
|
|
Invention
|
Amido heteroaromatic compounds. The specification relates to compounds comprising Formula (A) and... |
|
|
Invention
|
Uracil compounds. The specification relates to compounds of Formula (I) and to pharmaceutically a... |
|
|
Invention
|
Crystalline form of an amido heteroaromatic compound. The specification relates to a crystalline ... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of respiratory diseases and disorders |
|
|
Invention
|
Crystalline forms of tead inhibitor. The specification relates to physical forms of a TEAD inhibi... |
|
|
Invention
|
Londamocitinib for the treatment of asthma. A compound of Formula (I) or a pharmaceutically accep... |
|
|
Invention
|
Predicting response to neoadjuvant treatment in non-small cell lung cancer. The disclosure relate... |
|
|
Invention
|
Treatment of skin disease. The disclosure relates to methods and compositions for the treatment o... |
|
|
Invention
|
T cell binding compositions and methods. The disclosure generally relates to binding proteins tha... |
|
|
Invention
|
T cell binding compositions and methods.
The disclosure generally relates to binding proteins th... |
|
|
Invention
|
Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells.
The disclosur... |
|
|
Invention
|
Compounds and methods for reducing psd3 expression. Provided are double-stranded oligonucleotides... |
|
|
Invention
|
Il-5r-alpha antibodies for treating eosinophilic granulomatosis with polyangiitis. Provided herei... |
|
|
Invention
|
Treatment of gastric cancer and/or gastroesophageal junction cancer.
The disclosure relates to m... |
|
|
Invention
|
Treatment of gastric cancer and/or gastroesophageal junction cancer. The disclosure relates to me... |
|
|
Invention
|
Cell therapy.
Populations of cells for use in the treatment of heart disease and methods of maki... |
|
|
Invention
|
Cell therapy. Populations of cells for use in the treatment of heart disease and methods of makin... |
|
|
Invention
|
Azd1390, or a pharmaceutically acceptable salt thereof, in combination with radiation for use in ... |
|
|
Invention
|
Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells. The disclosure... |
|
|
Invention
|
Conjugates comprising cleavable linkers.
The specification relates to conjugates comprising a li... |
|
|
Invention
|
Multivalent cargo-carrying complexes and uses thereof.
Provided are multivalent saccharide-conta... |
|
|
Invention
|
Methods for purifying bispecific antibodies.
The present disclosure provides methods of purifyin... |
|
|
Invention
|
Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer. ... |
|
2023
|
Invention
|
Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer.
The specif... |
|
|
Invention
|
Combination therapy for treating cancer.
The present disclosure includes methods, pharmaceutical... |
|
|
Invention
|
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inh... |
|
|
Invention
|
A scoring method for an anti-fr alpha antibody drug conjugate therapy.
A method for predicting t... |
|
|
Invention
|
Method for predicting patient response to immunotherapy.
Methods for treating a patient having a... |
|
|
Invention
|
Anti-ifnar1 antibodies with reduced fc ligand affinity.
The invention provides anti-IFNAR1 antib... |
|
|
Invention
|
Compressible sodium caprate formulations.
The present disclosure provides a method of making an ... |
|
|
Invention
|
Methods of treating prostate cancer.
This disclosure relates to methods of treating prostate can... |
|
|
Invention
|
Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapaglifl... |
|
|
Invention
|
Methods of improving protein expression.
The present disclosure relates to nucleic acids that co... |
|
2022
|
Invention
|
Methods of treating brain tumours and neuroblastomas.
The present disclosure relates to methods ... |
|
|
Invention
|
Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators.
There are disclosed certain 3-a... |
|
|
Invention
|
Methods of treating biliary tract cancer using anti-pd-l1 antibody in combination with chemothera... |
|
|
Invention
|
Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as glp-1 receptor modula... |
|
|
Invention
|
Treatment of lupus.
The disclosure relates to methods and compositions for the treatment of Syst... |
|
|
Invention
|
Combinations with modulators of pnpla3 expression.
Provided are methods of treating a liver dise... |
